What is Evommune?
Evommune operates at the intersection of advanced immunology and drug development, focusing on the underlying drivers of chronic inflammation rather than mere symptom management. By leveraging a sophisticated pipeline, the company aims to deliver targeted therapies that offer superior patient outcomes. As a clinical-stage entity, Evommune has transitioned from its initial seed-stage development to a robust scaling phase, supported by a diverse syndicate of institutional investors and life sciences specialists who recognize the firm's potential to disrupt the current standard of care in dermatology and immunology.
How much funding has Evommune raised?
Evommune has raised a total of $185M across 3 funding rounds:
Angel/Seed
$12.5M
Series B
$57.5M
Series C
$115M
Angel/Seed (2020): $12.5M with participation from PIVOTAL BIOVENTURE PARTNERS LLC
Series B (2023): $57.5M led by Symbiosis Group, Arix Bioscience, and Verition Fund Management
Series C (2024): $115M supported by RTW Investments, Beiersdorf, Verition Fund Management, FemHealth Ventures, Amplitude Ventures, RA Capital Management, Marshall Wace, Andera Partners, ADAR1 Capital Management, Avego, Longwood Fund, Pivotal Bioventure Partners, Sectoral Asset Management, and B Capital Group
Key Investors in Evommune
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, from company creation to public companies.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies.
Longwood Fund
Longwood Fund is a venture capital firm that creates and invests in science-based companies focused on developing innovative solutions for significant medical challenges.
What's next for Evommune?
With the successful closure of its latest financing, Evommune is well-positioned to accelerate its clinical development programs. The strategic allocation of this capital will likely focus on advancing its lead candidates through critical trial milestones and expanding its research capabilities. As the company matures, the focus will shift toward validating its therapeutic platform in larger patient populations, potentially setting the stage for future commercialization or strategic partnerships within the global biopharmaceutical landscape.
See full Evommune company page
